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Skin disease may be related with immunological disorders, external aggressions, or
genetic conditions. Injuries or cutaneous diseases such as wounds, burns, psoriasis,
and scleroderma among others are common pathologies in dermatology, and in some
cases, conventional treatments are ineffective. In recent years, advanced therapies
using human mesenchymal stem cells (hMSCs) from different sources has emerged
as a promising strategy for the treatment of many pathologies. Due to their properties;
regenerative, immunomodulatory and differentiation capacities, they could be applied
for the treatment of cutaneous diseases. In this review, a total of thirteen types of
hMSCs used as advanced therapy have been analyzed, considering the last 5 years
(2015–2020). The most investigated types were those isolated from umbilical cord
blood (hUCB-MSCs), adipose tissue (hAT-MSCs) and bone marrow (hBM-MSCs). The
most studied diseases were wounds and ulcers, burns and psoriasis. At preclinical
level, in vivo studies with mice and rats were the main animal models used, and a
wide range of types of hMSCs were used. Clinical studies analyzed revealed that cell
therapy by intravenous administration was the advanced therapy preferred except in
the case of wounds and burns where tissue engineering was also reported. Although
in most of the clinical trials reviewed results have not been posted yet, safety was high
and only local slight adverse events (mild nausea or abdominal pain) were reported.
In terms of effectiveness, it was difficult to compare the results due to the different
doses administered and variables measured, but in general, percentage of wound’s
size reduction was higher than 80% in wounds, Psoriasis Area and Severity Index
and Severity Scoring for Atopic Dermatitis were significantly reduced, for scleroderma,
parameters such as Modified Rodnan skin score (MRSC) or European Scleroderma
Study Group activity index reported an improvement of the disease and for hypertrophic
scars, Vancouver Scar Scale (VSS) score was decreased after applying these therapies.
On balance, hMSCs used for the treatment of cutaneous diseases is a promising
strategy, however, the different experimental designs and endpoints stablished in each
study, makes necessary more research to find the best way to treat each patient
and disease.
Keywords: advanced therapy, cell therapy, dermatology, mesenchymal stem cells, skin diseases, skin injuries,
stem cells, tissue engineering
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INTRODUCTION
Human mesenchymal stem cells (hMSCs) are non-hematopoietic
multipotent adult progenitor cells that are found in multiple
tissues. They can be easily harvested and expanded from the
different tissues of adult donors, avoiding any potential ethical
issues for the development of new therapies (Mushahary et al.,
2018; Sierra-Sanchez et al., 2018).
The use of hMSCs for dermatological diseases seems to
be interesting due to (1) their hypo-immunogenic properties,
which allows its immediate use as prepared allogeneic cells
without significant host reaction (Koppula et al., 2009; Liang
et al., 2010; Lin and Hogan, 2011; Squillaro et al., 2016); (2)
their anti-inflammatory capacity (Di Nicola et al., 2002), that
can also be useful in dampening the inflammatory milieu of
chronic non-healing wounds and aid in the healing process, as
well as for the treatment of inflammatory chronic cutaneous
diseases; and (3) their possibility to differentiate into both
mesenchymal and non-mesenchymal lineages such as ectodermal
keratinocyte-like cells (KLCs) (Seo et al., 2016) and dermal cells
(He et al., 2007).
In addition, together with adult skin cells and skin stem cells,
the role of hMSCs in normal wound healing is also important.
They can contribute to re-epithelization by stimulating collagen
production and reducing fibrosis and scar formation by releasing
many growth factors such as epidermal growth factor (EGF),
transforming growth factor beta (TGF-β), vascular endothelial
growth factor (VEGF), and basic fibroblast growth factor (bFGF)
(Stone Ii et al., 2018).
For these reasons, the development and research of hMSC
based strategies in dermatology have increased in recent years
(Figure 1). The objective of this review is to summarize the recent
treatments (from 2015 to 2020) based on the use of hMSCs,
under research or applied in patients, to treat the most common
cutaneous injuries or diseases.
Abbreviations: bFGF, basic fibroblast growth factor; CHFS, cochin Hand
Function Scale; CT, cell therapy; DDEB, dominant dystrophic epidermolysis
bullosa; DEB, dystrophic epidermolysis bullosa; DNCB 2, 4-dinitrochlorobenzene;
EGF, epidermal growth factor; GT, gene therapy; hA-MSCs, human amnion
mesenchymal stem cells; hAT-MSCs, human adipose mesenchymal stem cells;
hBM-MSCs, human bone marrow mesenchymal stem cells; hDP-MSCs, human
dermal papilla mesenchymal stem cells; hDT-MSCs, human deciduous teeth
mesenchymal stem cells; hG-MSCs, human gingival mucosa mesenchymal
stem cells; hJM-MSCs, human jaw bone marrow mesenchymal stem cells;
hMen-MSCs, human menstrual fluid mesenchymal stem cells; hMSCs, human
mesenchymal stem cells; hP-MSCs, human placenta mesenchymal stem cells;
hPT-MSCs, human palatine tonsil derived mesenchymal stem cells; hUCB-
MSCs, human umbilical cord blood mesenchymal stem cells; hWJ-MSCs,
human wharton’s jelly mesenchymal stem cells; IMQ, imiquimod; KLCs,
keratinocyte-like cells; MCs, mast cells; MRSC, modified rodnan skin score;
PASI, psoriasis area and severity index; PDLLA, poly-D, L-lactic acid; PRP,
platelet-rich plasma; RDEB, recessive dystrophic epidermolysis bullosa; SCORAD,
severity scoring for atopic dermatitis; SDS, sodium dodecyl sulfate; SHAQ,
scleroderma health assessment questionnaire; SM, sulfur mustard; SOD3,
superoxide dismutase; SSc, systemic sclerosis; TBSA, total body surface area; TE,
tissue engineering; TESSs, tissue-engineered skin substitutes; TGF-β, transforming
growth factor beta; VEGF, vascular endothelial growth factor; VSS, vancouver
scar scale.
LITERATURE SEARCH METHODOLOGY
A literature search was performed using PubMed R© and
ClinicalTrials.gov from 01/01/2015 to 31/12/2020. The following
search terms were used: [(Mesenchymal Stem Cell) OR
(Mesenchymal Stromal Cell)] AND [(Wound Healing) OR
(Skin Wounds) OR (Skin Ulcers) OR (Burns) OR (Recessive
Dystrophic Epidermolysis Bullosa) OR (Psoriasis) OR (Atopic
Dermatitis) OR (Scleroderma) OR (Hypertrophic Scars)
OR (Skin Scars)].
Inclusion and Exclusion Criteria
The search in PubMed R© was limited to: (i) studies using hMSCs,
(ii) used as advanced therapy for skin conditions, (iii) in animals
or humans, and (iv) written in English or Spanish.
The search in ClinicalTrials.gov was limited to studies
where recruitment status was: (Recruiting) OR (Not yet
recruiting) OR (Active, not recruiting) OR (Completed) OR
(Enrolling by invitation) OR (Suspended) OR (Terminated).
Studies where recruitment status was (Withdrawn) OR
(Unknown) were excluded.
Reviews, guidelines, protocols, and conference
abstracts were excluded.
MESENCHYMAL STEM CELLS IN
CUTANEOUS INJURIES OR DISEASES
Wounds and Ulcers
Wound healing is a complex but well-orchestrated process
divided in four overlapping phases (hemostasis, inflammation,
proliferation, and remodeling) which plays a crucial role after a
cutaneous injury, restoring function and appearance of damaged
skin with minimal scarring (Reinke and Sorg, 2012). However,
many factors and diseases can provoke a deregulation of the
healing process, manifested as delayed wound healing (diabetes
and radiation exposure) or excessive healing (hypertrophic scars)
(Gurtner et al., 2008).
Preclinical in vivo Studies
At preclinical level (Table 1), since 2015, fourteen studies have
analyzed the use of hMSCs for wound healing therapies in mouse
or rat models. These cells have been isolated from different
human tissues such as adipose tissue (hAT-MSCs) (Li et al., 2016;
Hersant et al., 2019; Xiao et al., 2019; Zomer et al., 2020), bone
marrow (hBM-MSCs) (He et al., 2019), umbilical cord blood
(hUCB-MSCs) (Montanucci et al., 2017; Yang et al., 2017; Xu
et al., 2019; Myung et al., 2020; Zhang et al., 2020), Wharton’s
Jelly (hWJ-MSCs) (Ertl et al., 2018; Millán-Rivero et al., 2019),
dermal papilla (hDP-MSCs) (Zomer et al., 2020), placenta (hP-
MSCs) (Ertl et al., 2018), menstrual fluid (hMen-MSCs) (Cuenca
et al., 2018), amnion (hA-MSCs) (Ertl et al., 2018), and jaw bone
marrow (hJM-MSCs) (He et al., 2019). In one study the human
source of hMSCs was not indicated (Chen et al., 2017). First
conclusion is that all treatments based on hMSCs reported better
results in terms of wound healing comparing with non-advanced
or control therapies. Quantitave comparison of the effectiveness
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FIGURE 1 | Advanced therapy strategies based on the use of human mesenchymal stem cells (hMSCs) for the treatment of different cutaneous injuries or diseases.
Information included in brackets refers to the number of clinical studies reviewed between 2015 and 2020. This infographic also indicates the total number of
patients expected to be recruited for each pathology. Created with Biorender.com.
of the different hMSCs populations was difficult because in some
cases the numeric information was not provided and also, the
follow-up differed.
Cell therapy
Apart from the type of hMSCs, these studies were organized
according to the advanced therapy analyzed in each case
(Table 1). Most of the research used hMSCs as cell therapy (CT)
(Li et al., 2016; Cuenca et al., 2018; He et al., 2019; Hersant et al.,
2019; Xiao et al., 2019; Xu et al., 2019; Myung et al., 2020; Zhang
et al., 2020). Mean follow-up for this strategy was 15.4± 4.9 days
but routes of administration varied from direct application onto
the wounds (Hersant et al., 2019; Xu et al., 2019; Myung et al.,
2020), intradermal injection (Li et al., 2016; Cuenca et al., 2018),
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Cell therapy hAT-MSCs 1-hAT-MSC + SDF-1: intradermal
injection around the wound bed of
106 cells pretreated with SDF-1
2-hAT-MSC: intradermal injection
around the wound bed of 106 cells
Diabetic chronic skin
wounds




injections around each wound of
106 cells
Excisional wounds 14 days Cuenca et al.,
2018
hAT-MSCs 1-hAT-MSC from non-diabetic
patients: subcutaneous injection of
106 cells 2-hAT-MSC from diabetic
patients: subcutaneous injection of
106 cells






of 2 × 106 cells/mL 2-hJM-MSC:
intravenous injection of
2 × 106 cells/mL
Full-thickness skin
excision
12 days He et al., 2019
hAT-MSCs 1-hAT-MSC: Injection in the wound
of 2 × 105 cells
2-hAT-MSC + Plasma: Injection in
the wound of 2 × 105 cells with








1-hUCB-MSC: Injection in the
wound of 5 × 106 cells
2-hUCB-MSC + Hydrogel: Injection
in the wound of 5 × 106 cells with a
thermo-sensitive gel
Incision wounds 21 days Xu et al., 2019
hUCB-
MSCs
1-Irradiated wound treated with
hUCB-MSCs: Implantation onto the
wound bed of 1 × 105 cells in 30
µL Matrigel and subcutaneous
injection around the wound of
4 × 105 cells in 120 µL Matrigel
2-Irradiated wound treated with
hUCB-MSCs and PRP:
Implantation onto the wound bed of
1 × 105 cells in 30 µL PRP and
subcutaneous injection around the









injection around the wounds of 106
cells





hWJ-MSCs 1-Injected hWJ-MSC: injection of
106 cells in 100 µl buffered saline
solution 2-Skin substitute: wounds
covered by cellularized silk fibroin
scaffold (5 × 104 hWJ-MSC
seeded onto the scaffold for 4 days
before surgery) 3-Combined
therapy: wounds treated with
hWJ-MSCs injected at the edge
(106) and also cellularized silk
fibroin patches (5 × 104
hWJ-MSCs seeded onto the
scaffold for 4 days before surgery)
Excisional wounds 28 days Millán-Rivero
et al., 2019
(Continued)
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1-Dermal equivalent (DE): Fibrin
based scaffold mixed with
4 × 105 cells + 6 × 105 cells
2-Scaffold (S): Fibrin based scaffold
mixed with 4 × 105 cells








h-MSC cell sheets constituted of
10,000 cells/cm2 + 20,000 HUVEC
cells/cm2 on top + Autograft
Full thickness excision
wounds




1- hUCB-MSCs + Plasma: Platelet
poor plasma gel combined with
amnion (PPPA) + 106 hUCB-MSCs












Matriderm R© + 3 × 105 cells
(hA-MSCs alone, hP-MSCs alone
or hWJ-MSCs alone)
2-Prevascularized + hMSCs:
Matriderm R© + PLECs mixed with
the respective hMSC type in an
established 80:20 ratio





Integra R© associated with 106 cells
2-hAT-MSC: engrafment of
Integra R© associated with 106 cells
Excisional wounds 60 days Zomer et al.,
2020
and subcutaneous injection (Xiao et al., 2019; Zhang et al., 2020)
to intravenous injection (He et al., 2019).
hAT-MSCs were used in three studies (Li et al., 2016; Hersant
et al., 2019; Xiao et al., 2019). Li et al. (2016) compared the
use of hAT-MSCs (106 cells), hAT-MSCs (106 cells) pretreated
with stromal cell-derived factor 1 (SDF-1) and control group,
demonstrating that SDF-1 provided a protective effect on hMSCs
survival and, moreover, that increased wound closure potential of
diabetic chronic wounds. Xiao et al. (2019) analyzed the diabetic
or non-diabetic origin of hAT-MSCs, and their potential for
pressure ulcer wounds treatment, reporting that both populations
(106 cells of each) suppressed inflammatory response and
improved wound skin regeneration but wound healing was
better in the case of non-diabetic hAT-MSCs. Hersant et al.
(2019) studied the use of hAT-MSCs alone (2 × 105 cells) or
combined with 20% platelet-rich plasma (PRP) revealing that
wound closure were significantly higher in the combined therapy,
with more expression of human VEGF and SDF-1.
The another preferred hMSC population for these studies were
hUCB-MSCs, which were investigated in three articles also (Xu
et al., 2019; Myung et al., 2020; Zhang et al., 2020). Xu et al.
(2019) compared the use of hUCB-MSCs alone (5× 106 cells) or
in combination with an hydrogel, however, significant differences
in terms of wound healing were only observed against control
treatment groups without cells. Myung et al. (2020) design a
similar experiment but using PRP instead of and hydrogel.
In this case, the number of hUCB-MSCs used was 105 cells
and, only combined therapy (hUCB-MSCs + PRP) significantly
accelerated wound closure and enhanced neovascularization.
Interestingly, Zhang et al. (2020) analyzed the use of hUCB-
MSCs (106 cells), medium derived from hMSC cultures and
human fibroblasts (106 cells), demonstrating that hUCB-MSCs
or culture medium treatments accelerated wound healing by
enhancing angiogenesis.
Remaining studies which reported the use of hMSCs as CT
only, analyzed lesser-used sources such as hMen-MSCs (Cuenca
et al., 2018) or hJM-MSCs (He et al., 2019). In the first case,
106 hMen-MSCs were intradermally injected and compared with
a control treatment group demonstrating that wound closure
was higher and a well-defined vascular network was promoted
by hMen-MSCs (Cuenca et al., 2018). He et al. (2019) analyzed
the intravenous injection of hBM-MSCs (2 × 106 cells/mL) or
hJM-MSCs (2 × 106 cells/mL) reporting better results in terms
of wound closure against control group, but without significant
differences between both hMSCs sources.
Tissue engineering
Tissue engineering (TE) is another type of advanced therapy
which has been investigated for the treatment of wounds and
ulcers (Table 1). From 2015, five studies have reported the use
Frontiers in Cell and Developmental Biology | www.frontiersin.org 5 March 2021 | Volume 9 | Article 643125
fcell-09-643125 March 3, 2021 Time: 17:23 # 6
Sierra-Sánchez et al. Human Mesenchymal Stem Cells for Skin Diseases
of hMSCs to evaluate their potential clinical benefits as tissue-
engineered skin substitute (TESS) (Chen et al., 2017; Montanucci
et al., 2017; Yang et al., 2017; Ertl et al., 2018; Zomer et al., 2020).
Mean time of follow-up for this strategy was 29.2± 20.4 days and
the hMSCs populations analyzed were hUCB-MSCs (Montanucci
et al., 2017; Yang et al., 2017), hA-MSCs, hP-MSCs, hWJ-MSCs
(Ertl et al., 2018), hDP-MSCs, hAT-MSCs (Zomer et al., 2020),
and one where the source was not indicated (Chen et al., 2017).
In the case of hUCB-MSCs, different strategies were analyzed.
Montanucci et al. (2017) reported their use as part of a fibrin-
based scaffold only (4× 105 cells) or culturing hUCB-MSCs over
this scaffold (6 × 105 cells). These substitutes were transplanted
onto full-thickness lesions, and wounds treated with both cell
layers seemed to heal slower than those treated with fibrin-based
scaffold only, although the wound outcome at the end of the
study looked much better in the first case. Yang et al. (2017)
also administered hUCB-MSCs and compared their use as part
of a TESS constituted of platelet poor plasma gel, amnion and
106 cells or as CT (106 cells injected subcutaneously). Results
revealed that thickness of the newly formed epidermis layer of
the TESS group grew faster to cover the wounded skin tissue than
the CT and control groups.
Ertl et al. (2018) compared different hMSCs sources (hA-
MSCs, hP-MSCs, hWJ-MSCs) cultured over Matriderm R© alone
(3 × 105 cells) or in combination with placental endothelial
cells (PLECs). Interestingly, single application of each hMSC type
induced a better wound reduction than the co-applications with
PLECs. The best results in terms of wound healing were reported
by the use of hA-MSCs. Zomer et al. (2020) also compared two
types of hMSCs (hDP-MSCs, hAT-MSCs – 106 cells) associated to
Integra R©, demonstrating that these groups presented significantly
higher closure than control group (Integra R©).
Finally, Chen et al. (2017) evaluated the use of hMSCs sheets
(104 cells/cm2) pre-vascularized or not, as a support treatment for
gold standard therapy (autografts). Grafts from pre-vascularized
group preserved most skin appendages and supporting loose
connective tissues and on balance, transplantation of autografts
with hMSCs significantly accelerated wound healing.
Combined advanced therapy: cell therapy and tissue
engineering
Interestingly, one study evaluated a combined therapy of cell
therapy and tissue engineering (Table 1). In this research, hWJ-
MSCs were injected (106 cells) around the wounds, cultured
over a silk fibroin scaffold and transplanted (5 × 104 cells)
or both treatments were evaluated together. Results revealed
that combined therapy group displayed a collagen dermis
organization that was more similar to that typically observed
in the normal skin of mice and exhibited better wound
healing capabilities as compared with both single treatments
(Millán-Rivero et al., 2019).
Brief conclusion
On balance, potential benefits of these wound healing treatments
have been evaluated for four types of skin injuries: diabetic
chronic wounds (Li et al., 2016; Zhang et al., 2020), excisional
wounds (Cuenca et al., 2018; Ertl et al., 2018; He et al., 2019;
Hersant et al., 2019; Millán-Rivero et al., 2019; Xu et al.,
2019; Zomer et al., 2020), pressure ulcers wounds (Xiao et al.,
2019), and combined radiation and wound injuries (Myung
et al., 2020). Results revealed that both hMSCs’ strategies, CT
or TE, reported better results in terms of re-epithelialization,
wound closure and vascularization than control and other
treatment groups (autograft, injection of buffered saline solution,
or hydrogel without cells) (Table 1).
Clinical Studies
Considering the use of hMSCs for clinical purposes, sixteen
studies or clinical trials have been reviewed (Table 2). According
to the preclinical in vivo studies, advanced therapies preferred
have been cell therapy (8 studies) and tissue engineering (8
studies). The main source of hMSCs analyzed was hAT-MSCs
(7) although hWJ-MSCs (2), hUCB-MSCs (2), hBM-MSCs (1),
hP-MSCs (1), and non-indicated source of hMSCs (3) were also
analyzed. Considering the use of autologous or allogeneic cells,
allogeneic source was applied in most of the studies (14).
Cell therapy
The use of hMSCs as CT for the treatment of wounds and ulcers
is an interesting alternative against conventional therapies. In this
sense, from 2015 to 2020, eight studies have reported their use
(Table 2): two of them were case reports and results of efficiency,
in terms of wound’s size reduction, were published (Portas et al.,
2016; Mejía-Barradas et al., 2019).
Portas et al. (2016) evaluated the injection of 106 allogeneic
hBM-MSCs/ml around and within chronic radiation-induced
skin lesion of one patient (66 years old). After 3 months,
wound size was completely reduced without non-adverse events.
Moreover, the use of hBM-MSCs reduced inflammation process
(marked decrease of β1 integrin expression on lymphocytes) and
improved vasculature and quality of the skin.
Mejía-Barradas et al. (2019) studied the intradermal injection
around and within the lesion of 105 allogeneic hWJ-MSCs/cm2,
in one patient (41 years old) with chronic ulcers (42 cm2)
reporting an effectiveness of 75%, considering wound size
reduction after 14 days. Neo-vascularization and formation of
collagen fibers were also observed in regenerated skin and the
number of proinflammatory cytokines decreased.
Rest of studies reviewed were clinical trials (Phase I or Phase
I/IIa), however, no published results are posted at this time. One
of them analyzed the topical application of autologous hMSCs
on the wound surface for the treatment of chronic venous leg
ulcers (NCT02742844), meanwhile, the rest evaluated allogeneic
cells such as hUCB-MSCs (NCT04219657 and NCT04104451),
hP-MSCs (NCT04464213), or hMSCs (NCT03257098 and
NCT03267784) for the treatment of different types of wounds
(diabetic foot ulcers, traumatic heel pad injuries and chronic
venous leg ulcers).
Considering protocols approved for all these studies, there is
not a preferred source of hMSCs for the development of cell
therapy strategies for wounds and ulcers, although in all cases,
cells will be applied or injected around and into the wounds to
evaluate their potential clinical safety and effect.
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aExpression of measures: mean +/− standard deviation (range).
1A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-101 Clinical Trial – Full Text View – ClinicalTrials.gov Available at: https://clinicaltrials.gov/ct2/show/NCT03183726 [Accessed January
13, 2021].
2Allogeneic ABCB5-positive Stem Cells for Treatment of CVU – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/NCT03257098?term=mesenchymal+stem+cells&cond=Wound+
of+Skin&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=4 [Accessed January 11, 2021].
3Allogeneic ABCB5-positive Stem Cells for Treatment of DFU “Malum Perforans” – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/study/NCT03267784?term=mesenchymal+
stem+cells&cond=Skin+ulcer&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=19 [Accessed January 13, 2021].
4Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Foot Ulcers – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/study/NCT03754465?term=mesenchymal+stem+
cells&cond=Skin+ulcer&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=13 [Accessed January 13, 2021].
5Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/study/NCT04497805?term=
mesenchymal+stem+cells&cond=Skin+ulcer&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=10 [Accessed January 13, 2021].
6Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers. – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/study/NCT03370874?
term=mesenchymal+stem+cells&cond=Skin+ulcer&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=12 [Accessed January 13, 2021].
7Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/study/NCT02619877?
term=mesenchymal+stem+cells&cond=Skin+ulcer&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=11 [Accessed January 13, 2021].
8Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers. – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/
NCT04569409?term=mesenchymal+stem+cells&cond=Skin+ulcer&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=21 [Accessed January 13, 2021].
9Clinical Trial to Investigate Efficacy and Safety of the IMP in Patients With Non-Healing Wounds Originating From Ulcers – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/
NCT02742844?term=mesenchymal+stem+cells&cond=Wound+of+Skin&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=1&rank=6 [Accessed January 11, 2021].
10Comparison Between Skin Graft Versus Skin Graft and Stem Cell Application – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/study/NCT04219657?term=mesenchymal+stem+
cells&cond=Wound+of+Skin&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=1 [Accessed January 11, 2021].
11Human Placental Mesenchymal Stem Cells Treatment on Diabetic Foot Ulcer – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/NCT04464213?term=mesenchymal+stem+cells&
cond=Skin+ulcer&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=3 [Accessed January 11, 2021].
12PHASE 1, OPEN-LABEL SAFETY STUDY OF UMBILICAL CORD LINING MESENCHYMAL STEM CELLS (CORLICYTE R©) TO HEAL CHRONIC DIABETIC FOOT ULCERS – Full Text View – ClinicalTrials.gov Available
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Tissue engineering
From 2015, eight studies have evaluated the use of hMSCs as
a component of TESSs for the treatment of diabetic foot ulcers
(Table 2). Until now, only three of them have published results of
safety and effectiveness (Hashemi et al., 2019; Moon et al., 2019;
Stessuk et al., 2020).
Seven studies evaluated the use of allogeneic hMSCs isolated
from adipose tissue (6) or Wharton’s Jelly (1) and one study
reported the use of autologous hAT-MSCs. Most of them were
Phase I, II, or III clinical trials although one of them was an
observational study (NCT03183726).
In all cases, strategy was based on manufacturing sheets
of different biomaterials combined with the different hMSCs
sources to evaluate their engraftment into diabetic foot
ulcers. Those studies with published results applied different
hMSCs: allogeneic hWJ-MSCs (Hashemi et al., 2019), allogeneic
hAT-MSCs (Moon et al., 2019) and autologous hAT-MSCs
(Stessuk et al., 2020).
Hashemi et al. (2019) evaluated the engraftment of an acellular
amniotic membrane seeded with hWJ-MSCs in 5 patients. No
adverse events were reported, and wound size after 9 days
significantly declined (96.7% from original size).
Moon et al. (2019) (NCT02619877) manufactured hydrogel
sheets containing 106 allogeneic hAT-MSCs/sheet for the
treatment of 22 patients with diabetic foot ulcers and compared
the results with a standard treatment (17 patients). Outcomes
revealed that no serious adverse events were observed, complete
wound closure was achieved for 82% in the treatment group
and 53% in the control group at week 12 and Kaplan-Meier
median times to complete closure were 28.5 and 63.0 days for the
treatment group and the control group, respectively.
In a case where autologous hAT-MSCs were used to fabricate
bio-membranes constituted of 107 hAT-MSCs and platelet-
rich plasma, 6 patients were treated. Conclusions revealed that
there was granulation tissue formation starting from 7 days
after topical application and after 90 days, a healed and re-
epithelialized tissue was observed. No adverse events were
reported (Stessuk et al., 2020).
Remaining studies reviewed have not published results yet
(NCT04497805, NCT03370874, NCT03754465, NCT03183726,
and NCT04569409), but incorporation of hAT-MSCs into a
hydrogel was the methodology selected in all cases.
Brief conclusion
On balance, preferred hMSC population for the treatment of
wounds and ulcers are the allogeneic hAT-MSCs, mainly as tissue
engineering strategy. Although information about the results is
limited and the standardization of a cell dose is difficult, the use
of hMSCs could improve the treatment of patients with these skin
conditions, because published results are hopeful.
Considering only those studies were results were posted from
2015 to 2020, 35 patients have been treated (2 with CT strategy
and 33 with TE strategy), all of them with chronic skin ulcers
(associated to diabetes or not) and a range of wound size between
0.71 and 48 cm2. The weighted mean effectiveness, based on
the wound’s size reduction, was of 87.5 ± 12.5% for the CT
treatments (closure time: from 7 to 90 days) and 82.7 ± 5.8% for
TE therapies (closure time: from 9 to 90 days).
Burn Injuries
The majority of burn injuries are minor and either do not
require treatment or can be treated by any caregiver, however,
in the case of severe burns they can lead to a profound systemic
response and have serious long-term effects on patients (Porter
et al., 2016). Moreover, failure to properly treat these injuries
will lead to rapid development of organ failure and death
(Greenhalgh, 2019).
Preclinical in vivo Studies
At preclinical level, five studies [one CT (Pourfath et al., 2018)
and four TE strategies (Steffens et al., 2017; Kaita et al., 2019;
Mahmood et al., 2019; Nazempour et al., 2020)] have evaluated
the use of hMSCs for burn injuries in the last 5 years (Table 3).
Cell therapy
Pourfath et al. (2018) evaluated a cell spray application of 5× 105
hWJ-MSCs over third degree burns. After 21 days of follow-up,
wounds showed a higher degree of re-epithelialization compared
to the control group, and hemorrhage was also completely ceased
by the end of the second week post application (Table 3).
Tissue engineering
In this case, each of the four studies reported, used a different
hMSCs population (Table 3): deciduous teeth (hDT-MSCs)
(Steffens et al., 2017), hUCB-MSCs (Mahmood et al., 2019), hAT-
MSCs (Kaita et al., 2019) and hWJ-MSCs (Nazempour et al.,
2020). The average follow-up of these studies was 15.5± 5.9 days
and third-degree burns in mice and rats was the preferred model,
although the type of TESS evaluated varied.
Steffens et al. (2017) embedded hDT-MSCs into a poly-D,
L-lactic acid (PDLLA) scaffold and included 105 keratinocytes.
Apart from that, they also evaluated the incorporation, or not,
of laminin-332 to the design. Considering average size of the
lesions, no statistical difference between the different groups were
observed, although those groups which incorporated laminin-
332 reported a greater reduction.
Mahmood et al. (2019) analyzed an interesting approach
where hUCB-MSCs were in vitro differentiated into fibroblasts
and keratinocytes. Derived fibroblasts (2.5 × 104 cells) were
embedded into a plasma scaffold and then, derived keratinocytes
(3 × 104 cells) were overlaid. This was compared with a control
group without any treatment, revealing that contraction was
97.6 ± 0.61% for hUCB-MSCs group against 87.57 ± 1.30% in
control group and complete healing was faster for hUCB-MSCs
group (20.00± 2.00 vs. 27.67± 2.51 days).
Kaita et al. (2019) studied if differences between fresh hAT-
MSCs (5 × 104) or frozen hAT-MSCs (5 × 104) cultured over
an artificial dermis exists. Results indicated that after day 12 post
treatment, a significant difference in the percentage of wound
closure was observed between the hAT-MSCs groups and control
group but expression of Type I and III collagen was higher when
frozen hAT-MSCs were used.
Finally, Nazempour et al. (2020) evaluated the use of 2 × 106
hWJ-MSCs seeded onto acellular dermal matrix scaffold and
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Cells Type of hMSC treatment evaluated Type of wound
analyzed
Follow-up References
Cell therapy hWJ-MSCs 1-hWJ-MSC: 5 × 105 cells using cell spray
method




hDT-MSCs 1-hDT-MSCs + poly-D,L-lactic acid
(PDLLA) + laminin-332 protein (lam): 105
cells + 105 keratinocytes + scaffold 2-
hDT-MSCs + PDLLA: 105 cells + 105
keratinocytes + scaffold




1-hUCB-MSC + plasma: 2.5 × 104 derived
fibroblast cells + 3 × 104 derived keratinocyte
cells + scaffold
Burn injury 20 days Mahmood
et al., 2019
hAT-MSCs 1-Fresh hAT-MSCs: 5 × 104 cells on artificial




12 days Kaita et al.,
2019
hWJ-MSCs 1-hWJ-MSC + acellular matrix: 2 × 106
hWJSCs seeded onto acellular dermal matrix
scaffold
Third-degree burn 21 days Nazempour
et al., 2020
compared the results with a conventional treatment (silver
sulfadiazine ointment). Wound size decreased in a better way in
group where hWJ-MSCs were used (87.6%).
Brief conclusion
In conclusion, for burn injuries the purpose is to develop a
TESS which could supply the lack of health tissue around the
wounds. Although, there is not a preferred hMSCs source and
more investigation to find the best scaffold is required, it is clear
that the use of advanced therapy could improve the treatment of
these injuries, even when frozen cells are used.
Clinical Studies
For clinical purposes, six studies or clinical trials have
investigated the use of hMSCs for the treatment of burn injuries
(Table 4). In contrast to the tendency observed in the case of
preclinical in vivo studies analyzed, the advanced therapy most
studied was CT (4 studies vs. 2 studies in the case of TE). Three
sources of hMSCs were applied: hAT-MSCs (3), hBM-MSCs (2),
and hUCB-MSCs (2). Allogeneic cells were used in four studies
and autologous cells only in one. One clinical trial did not define
the use of allogeneic or autologous hAT-MSCs (NCT03686449).
Cell therapy
Since 2015, four studies have evaluated the use of CT for the
treatment of severe burn thermal (or not) injuries where a full-
thickness skin were lost (Table 4). Two research rereviewed
were case report (Mansilla et al., 2015; Jeschke et al., 2019)
and the other two were clinical trials (Abo-Elkheir et al.,
2017) and (NCT03686449) although in the second case, no
results were posted.
Mansilla et al. (2015) reported the use of allogeneic hBM-
MSCs in one patient (26 years old) by topical application of
106 hBM-MSCs per 100 cm2, combined with autologous meshed
skin grafting for severe thermal burns. No adverse events were
observed and after 35 days of treatment, with two courses of
hBM-MSCs, the complete epithelialization of the wounds were
too slow. The other case report used allogeneic hUCB-MSCs
for the treatment of severe burns injuries of one patient (Total
Body Surface Area-TBSA-affected of 70%). 3 × 106 cells/mL
were applied topically and results revealed that 97% of wounds
were closed with minimal hyperpigmentation and hypertrophic
scarring (Jeschke et al., 2019).
One of the clinical trials included, compared the use
of a suspension constituted of hAT-MSCs and autologous
keratinocytes with other alternative treatments, however, no
results were posted (NCT03686449).
Abo-Elkheir et al. (2017) published the results of an interesting
clinical trial where compared three types of treatments for
thermal full thickness burns: autologous hBM-MSCs (2 injections
in the burned area – 1 ml/cm2 of 105 hMSC/ml suspension),
allogeneic hUCB-MSCs (topical application and injection) and
early excision and graft-treated group (N = 20 for each group).
Safety results revealed that in the case of hBM-MSCs; 25% of
cases presented early complications (infection or partial loss of
graft) and 45% late complications (hypo- or hyperpigmentation,
contracture scar or hypertrophic scar), in the case of hUCB-
MSCs; 70% of cases presented early complications and late
complications and in the control group; 50% of cases presented
early complications and 95% late complications. Percentage of
burn extent was significantly reduced in both hMSC groups as
compared to early control group.
Tissue engineering
Two clinical trials (interventional and observational) evaluated
the use allogeneic hAT-MSCs as part of a hydrogel sheet for
the treatment of second-degree burn wounds (NCT02394873
and NCT03183622), however, no results have been posted
yet (Table 4).
Brief conclusion
On balance, at clinical level the preferred hMSC-based advanced
therapy is CT in contrast with preclinical studies where the TE
is the most investigated. This means that researches are focusing































































































































































































































































































Clinical Trial – Full
Text View –
ClinicalTrials.gov)2
aExpression of measures: mean ± standard deviation (range).
1A Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Deep Second-degree Burn Wound – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/NCT02394873?term=
mesenchymal+stem+cells&recrs=abdefgh&cond=burns&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=5 [Accessed January 13, 2021].
2A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-101 Clinical Trial – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/study/NCT03183622?term=
mesenchymal+stem+cells&recrs=abdefgh&cond=burns&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=6 [Accessed January 13, 2021].
3Autologous Keratinocyte Suspension Versus Adipose-Derived Stem Cell-Keratinocyte Suspension for Post-Burn Raw Area – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/
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on develop TESS that mimics native skin in a better way, however,
more investigation is required and for these reason the translation
of CT therapies (which were more studied in the previous years)
is more widespread.
Considering all clinical studies reviewed, 42 patients have
been recruited to analyze the potential benefits of hMSCs for the
treatment of burn injuries. Most of the studies used allogeneic
hMSCs but, in some cases results, were not successful (Mansilla
et al., 2015), in contrast to one case where the comparison
between autologous or allogeneic CT strategy reported that the
best wound closure was achieved when autologous hBM-MSCs
were used. In the same study, safety parameters revealed that
the use of autologous cells was less dangerous for the patient’s
health (Abo-Elkheir et al., 2017). However, rest of studies which
evaluated the use of allogeneic cells did not report the presence of
adverse events. The weighted mean TBSA treated with hMSCs-
based CT strategies has been 18.8± 10.4%, until now.
Recessive Dystrophic Epidermolysis
Bullosa
Dystrophic epidermolysis bullosa (DEB) is a genetic skin
disorder that usually presents at birth. It is due to the presence
of pathogenic variants of the gene COL7A1 and depending
on inheritance pattern is divided into two types: dominant
dystrophic epidermolysis bullosa (DDEB) and recessive
dystrophic epidermolysis bullosa (RDEB). In DDEB, blistering
is often mild but nonetheless heals with scarring. In the case
of RDEB, clinical disorders are severe including skin fragility
manifest by blistering with minimal trauma that heals with milia
and scarring, even in in the neonatal period and therefore, the
lifetime risk of aggressive squamous cell carcinoma is higher
than 90% (Pfendner and Lucky, 2018).
Preclinical in vivo Studies
Recessive dystrophic epidermolysis bullosa is a rare disease and
for this reason the number of studies in the last 5 years is
limited (Table 5). In addition, due to their genetic etiology its
study requires complex techniques of genetic engineering which
long-term effect in humans is yet unknown.
At preclinical level (Table 5), only two studies have
investigated the use of hBM-MSCs (Kühl et al., 2015) or hUCB-
MSCs (Petrova et al., 2020). Interestingly, these studies show
a different strategy to evaluate the potential effect of advanced
therapies for RDEB. In the first case, Kühl et al. (2015) used a
hypomorphic mouse model of dystrophic epidermolysis bullosa,
meanwhile, Petrova et al. (2020) developed TESS manufactured
with RDEB fibroblasts and keratinocytes and compared the
results with a TESS fabricated with hUCB-MSCs transduced with
COL7A1 gene.
Kühl et al. (2015) evaluated a cell therapy for 12 weeks where
after provoking full thickness skin wounds, 2 × 106 hBM-MSCs
were injected at the wound edges at 8 and 56 h after generating
the wounds. Results revealed that after 3, 6, and 7 days, the
MSC-injected wounds remained significantly smaller than PBS-
injected wounds (day 3, 38.1 ± 2.7% vs. 59.3 ± 6.4%; day 6,
30.3 ± 2.4% vs. 39.7 ± 4.1%; and day 7, 21.8 ± 1.6% versus
31.8± 4.7%) and moreover, after 12 weeks, healed MSC-injected
hypomorphic wounds contained 2.1 ± 0.5 immature anchoring
fibrils/µm lamina densa with a thickness of 19.6 ± 1.3 nm
which was lower than wild-type skin (3.8 ± 0.3 anchoring
fibrils/µm lamina densa with an average maximal thickness of
32.5 ± 1.6 nm), but fibrils were clearly functional and stabilized
the skin (Kühl et al., 2015).
Research by Petrova et al. (2020) combined CT, TE and gene
therapy (GT) which are the three types of advanced therapies.
In this case, full-thickness wounds were generated and then
devitalized. Authors manufactured three types of TESSs: (i)
RDEB fibroblasts mixed with COL7A1-transduced hUCB-MSCs
at a 1:1 ratio and primary RDEB keratinocytes seeded on top;
(ii) RDEB fibroblasts alone and primary RDEB keratinocytes
seeded on top; and (iii) wild type fibroblasts alone and wild
type keratinocytes seeded on top. In addition, after 6–8 weeks
mice received two intradermal injections of 0.5 × 106 COL7A1-
transduced hUCB-MSCs or 2× 106 COL7A1-transduced hUCB-
MSCs via tail vein (controls without cells were also injected).
Results revealed that mice treated with TESSs constituted of
hUCB-MSCs had an abundance of sublamina densa fibrillary
structures that bore the ultrastructural characteristics of normal
anchoring fibril. Evaluating cell therapy, small blisters were seen
in the control intradermal-injected animals but not in the animals
that received hUCB-MSCs intradermal injection. No evidence
were observed that systematically injected hUCB-MSCs migrated
to sites of skin grafts.
On balance, the use of hMSCs for the treatment of RDEB it is
a promising strategy, however, due to genetic conditions of the
disease, the combination of different advanced therapies seems to
be the best option which implies more preclinical studies before
translating to the clinical environment.
Clinical Studies
Since 2015, seven clinical trials have evaluated the use of hMSCs
as CT strategy for the treatment of RDEB (Table 5). All of
them used allogeneic hMSCs ant the most studied population
was hBM-MSCs (5), although hUCB-MSCs (1) and not-defined
hMSCs (1) were also analyzed.
Petrof et al. (2015) evaluated the application of three
intravenous injections of allogeneic hBM-MSCs (1×106 cells/kg
to 3 × 106 cells/kg) in 10 patients (4.8 ± 3.8 years old). They
reported that most of the adverse events observed were not
related to the hBM-MSCs and after 180 days of follow-up skin
biopsies revealed no increase in type VII collagen expression and
no new anchoring fibrils formation but quality of life increased
and pain decreased.
Similar clinical studies were developed by Ebens et al.
(NCT02582775) and Rashidghamat et al. (NCT02323789). In
each clinical trial 10 patients received intravenous infusions of
hBM-MSCs [2× 106 cells/kg to 4 × 106 cells/kg (Rashidghamat
et al., 2020)]. In the case of Ebens et al. two of the transplants
provoked veno-occlusive disease of the liver and 1 of the patients
developed graft versus host disease (Ebens et al., 2019). After
1 year of follow-up, skin biopsies showed stable (n = 7) to
improved (n = 2) type VII collagen protein expression and gain of
anchoring fibril components (n = 3) (Ebens et al., 2019) and total



























TABLE 5 | Preclinical in vivo and clinical studies of hMSCs used as advanced therapy for recessive dystrophic epidermolysis bullosa in the last 5 years.




Cells Disease model and Treatments Animals Type of wound analyzed Follow-up References
Cell therapy hBM-MSCs 1–8 h after wounding, 2 × 106
hBM-MSCs were injected at the wound
edges and this procedure was repeated
48 h after the first injection 2–8 h after
wounding, PBS alone were injected at
the wound edges and this procedure







Two full thickness skin
wounds were incised at
the mid-back






hUCB-MSCs 1-Skin substitute constituted of RDEB fibroblasts mixed with
COL7A1-transduced MSCs at a 1:1 ratio. Primary RDEB
keratinocytes were then seeded on top 2-Skin substitute
constituted of RDEB fibroblasts alone. Primary RDEB
keratinocytes were then seeded on top 3-Skin substitute
constituted of wild type fibroblasts alone. Wild type
keratinocytes were then seeded on top 4-After 6–8 weeks mice
treated with human skin substitutes received two intradermal
injections of 0.5 × 106 engineered MSCs in 50 ul buffered
saline solution each or injected with 2 × 106 engineered MSCs
in 150 ul buffered saline solution via tail vein. Controls without
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Bullosa – Full Text
View –
ClinicalTrials.gov)1
aExpression of measures: mean ± standard deviation (range).
1Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/NCT03529877?term=mesenchymal+stem+cells&
recrs=abdefgh&cond=Recessive+Dystrophic+Epidermolysis+Bullosa&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=3 [Accessed January 13, 2021].
2Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa – Full Text View – ClinicalTrials.gov Available at: https://clinicaltrials.gov/ct2/show/NCT02323789 [Accessed February 14, 2021].
3MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs – Full Text View – ClinicalTrials.gov Available at: https://clinicaltrials.gov/ct2/show/NCT02582775 [Accessed February 14,
2021].
4Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/
NCT04520022?term=mesenchymal+stem+cells&recrs=abdefgh&cond=Recessive+Dystrophic+Epidermolysis+Bullosa&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=1 [Accessed January 13,
2021].
5Safety Study and Preliminary Efficacy of Infusion Haploidentical Mesenchymal Stem Cells Derived From Bone Marrow for Treating Recessive Dystrophic Epidermolysis Bullosa – Full Text
View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/NCT04153630?term=mesenchymal+stem+cells&recrs=abdefgh&cond=Recessive+Dystrophic+Epidermolysis+Bullosa&strd_s=01%2F01%
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blister count over the entire body surface area showed a decrease
compared with baseline (Rashidghamat et al., 2020).
El-Darouti et al. (2016) also used hBM-MSCs for the treatment
of RDEB but in this case, they compared the intravenous injection
of these cells (70 × 106 cells to 150 × 106 cells) with or without
a cyclosporine suspension (5 mg/kg) in 14 patients. No adverse
events were observed in any of the and the mean number of
new blister formation decreased from 43 ± 21.2 to 9 ± 10.97
in cyclosporine’s group and from 49 ± 1.8 to 13 ± 8.5 in
the other group. After 1 year, improvement was continuous in
two patients from cyclosporine’s group, whereas the remaining
patients showed gradual loss of improvement.
Finally, other three clinical trials evaluated the use
of allogeneic hUCB-MSCs (NCT04520022), allogeneic
haploidentical hBM-MSCs (NCT04153630) and allogeneic
hMSCs (NCT03529877). In all cases the route of administration
was intravenous injection (3 doses of 2 × 106 cells/kg to 3 × 106
cells/kg), however, no results are posted.
On balance, advanced therapies based on the use of hMSCs
for the treatment of RDEB seems to be a promising strategy,
although more research is required. Until now, all clinical studies
have evaluated the use of these cells as cell therapy, however, at
preclinical level, one study has investigated the combination of
CT, TE, and GE, but its translation to a clinical environment
is still far from achieving. The genetic conditions of the disease
and the lack of long-term information about genetic modification
of cells are a big handicap. Considering the cell source, hBM-
MSCs were the population most used (5/7) and the route of
administration preferred was intravenous injection.
Psoriasis
Psoriasis is a long-term (chronic) inflammatory skin disease
with a strong genetic predisposition and autoimmune pathogenic
traits that causes erythematous, itchy scaly patches. Worldwide
prevalence is about 2% (Christophers, 2001). Five types of
psoriasis have been reported: (i) plaque psoriasis or psoriasis
vulgaris; (ii) eruptive psoriasis, which is characterized by
scaly teardrop-shaped spots; (iii) inverse psoriasis, also called
intertriginous or flexural psoriasis that is usually found in folds
of skin; (iv) pustular psoriasis; and (v) erythrodermic psoriasis,
which is a rare but very serious complication of psoriasis
(Boehncke and Schön, 2015).
Due to the etiology of the psoriasis, the anti-inflammatory
and immunomodulatory capacities of hMSCs (Di Nicola et al.,
2002) have emerged as a useful tool for the development
of possible advanced therapies, mainly CT. Their potential
has been demonstrated in vitro, being capable of restoring
the physiological phenotypical profile of psoriatic MSCs
(Campanati et al., 2018).
Preclinical in vivo Studies
Since 2015, five in vivo studies have evaluated the potential use
of hMSCs as CT for psoriasis (Table 6; Sah et al., 2016; Lee et al.,
2017; Kim J.Y. et al., 2018; Chen et al., 2019; Imai et al., 2019). To
that purpose, in all cases, researches induced the disease through
the topical application of imiquimod (IMQ), except in the case of
Yun-Sang et al. (Lee et al., 2017) where psoriasis was induced by
intradermal injection of IL-23.
Interestingly, one study combined CT with GT strategy (Sah
et al., 2016) where 2× 106 hUCB-MSCs injected subcutaneously
were transduced with extracellular superoxide dismutase (SOD3)
demonstrating that enhanced the immunomodulatory and
antioxidant activities of hMSCs and therefore, prevented
psoriasis development after 12 days of follow-up.
Rest of the reports studied hUCB-MSCs (Lee et al., 2017; Chen
et al., 2019), palatine tonsil (hPT-MSCs) (Kim J.Y. et al., 2018) or
hA-MSCs (Imai et al., 2019) as CT strategy for 10 ± 4.8 days.
Studies which evaluated the use of hUCB-MSCs demonstrated
that proinflammatory cytokines such as IL-6, IL-17, and TNF-α
were inhibited but IL-10 was significantly increased (Lee et al.,
2017; Chen et al., 2019). Lee et al. (2017) injected subcutaneously
2 × 106 cells on days 1 and 7 after induction of psoriasis-like
skin meanwhile, Chen et al. (2019) injected intravenously 1× 105
cells, but in both cases, hUCB-MSCs did not only prevent but also
treat psoriasis-like skin (Lee et al., 2017; Chen et al., 2019).
In the case where hPT-MSCs (106 cells) and hA-MSCs
(2 × 105 cells) were applied, intravenous injection was the route
of administration chosen and, in both cases, suppressed the
development of psoriasis (Kim J.Y. et al., 2018; Imai et al., 2019).
On balance, results using hMSCs were better than control
groups in all cases and two studies used the Psoriasis Area
and Severity Index (PASI); demonstrating in both cases that
after 7 to 8 days, PASI values were lower for hMSCs-treated
groups (4.5) than non-treated groups (6.5) (Kim J.Y. et al., 2018;
Chen et al., 2019).
Clinical Studies
Over the past 5 years, nine clinical studies have reported the use of
hMSCs for the treatment of different types of psoriasis: psoriasis
vulgaris (Chen et al., 2016; De Jesus et al., 2016) (NCT03765957),
psoriatic arthritis (De Jesus et al., 2016), moderate to severe
psoriasis (Comella et al., 2018) (NCT03265613, NCT03392311,
and NCT04275024) and plaque psoriasis (Wang et al., 2020)
(NCT02918123) (Table 7).
All studies applied CT strategies, two of them used autologous
hAT-MSCs (De Jesus et al., 2016; Comella et al., 2018) and the
others, evaluated the use of allogeneic cells from different sources:
hUCB-MSCs (Chen et al., 2016) (NCT03765957, NCT02918123),
hAT-MSCs (NCT03265613, NCT03392311, NCT04275024), and
gingival mucosa MSCs (hG-MSCs) (Wang et al., 2020).
Results were reported in the four case reports analyzed
(Chen et al., 2016; De Jesus et al., 2016; Comella et al., 2018;
Wang et al., 2020) and despite of the fact that different hMSCs
populations were used, adverse events were not observed in none
of them.
Chen et al. (2016) evaluated the use of allogeneic hUCB-
MSCs by 1–3 infusions (doses of 106 cells/kg) in 2 patients with
psoriasis vulgaris. After a follow-up of 4–5 years no symptoms of
psoriatic relapse were observed. Something similar occurred in
the study of Wang et al. (2020) were hG-MSCs were administered
by bolus injections (5 doses of 3 × 106/kg) in a patient with
plaque psoriasis, demonstrating that after 3 years the disease
was resolved.
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1-hUCB-MSC group: 2 × 106 cells
injected subcutaneously 24 h before
and at day 6 of imiquimod application
2-hUCB-MSC-transduced group:
2 × 106 cells transduced with
extracellular superoxide dismutase
(SOD3) and injected subcutaneously
24 h before and at day 6 of imiquimod
application 3-Control group:
subcutaneous injections of an equal
volume of phosphate-buffered saline at
the same time points




12 days Sah et al., 2016
Cell therapy hUCB-
MSCs
1-hUCB-MSC group: 2 × 106 cells
were injected subcutaneously on day 1
and 7 after induction of psoriasis-like
skin 2-Control group: subcutaneous
injections of an equal volume of
phosphate-buffered saline at the same
time points










15 days Lee et al., 2017
hPT-MSCs 1-hPT-MSC group: 106 cells via the
mouse tail vein on days 1 and 3 of the
imiquimod application period 2-Control
group: Mice received an intravenous
injection of an equal volume of
phosphate-buffered saline (PBS) via tail








7 days Kim J.Y. et al.,
2018
hA-MSCs 1-hA-MSC group: 2 × 105 cells
injected intravenously 2-Control group:
mouse serum injected intravenously




5 days Imai et al., 2019
hUCB-
MSCs
1-hUCB-MSC group: 1 × 105 cells
injected intravenously 2-Control group:
phosphate-buffered saline injected
intravenously




13 days Chen et al.,
2019
In contrast, De Jesus et al. (2016) and Comella et al. (2018)
applied autologous hAT-MSCs injected intravenously [2–3 doses
of 0.5–3.1 × 106 cells/kg or a unique dose of 6 × 107 cells].
In the first case, significant improvement was noted in lesions
of 2 patients with psoriasis vulgaris and psoriatic arthritis (PASI
changed from 21 to 9 and from 24 to 8.3, respectively) and joint
pain was reduced, meanwhile, in the second case, psoriasis area
and severity PASI score decreased from 50.4 at baseline to 0.3 at
1-month follow-up (Comella et al., 2018).
Rest of studies reviewed were clinical trials, but no results
have been posted yet. In these, allogeneic hAT-MSCs (3)
or hUCB-MSCs (2) alone (NCT03765957, NCT03265613, and
NCT02918123) or in combination with other treatments such
as calcipotriol ointment (NCT033923119) or oral PSORI-CM01
Granule (NCT04275024) has been evaluated. Type of treatments
varied from doses of 5 × 105 cells/kg to a unique injection of
2 × 108 cells and the preferred source of administration was
intravenously although one study analyzed the application of
subcutaneous injections (NCT02918123).
According to the investigations reviewed, at preclinical and
clinical level, for the treatment of different types of psoriasis the
best advanced therapy based on the use of hMSCs is cell therapy.
Results in most of the cases demonstrated a decrease of the PASI
values and in some patients, psoriasis disappeared. Considering
the route of administration, intravenous injections are the most
analyzed and the most promising hMSC populations are hAT-
MSCs and hUCB-MSCs, although more research is required to
standardize the dose and determine the autologous or allogeneic
nature of the cells.
Atopic Dermatitis
Atopic dermatitis is a chronic inflammatory pruritic skin disease
that affects a large number of children and adults (Akdis et al.,
2006), although it can improve significantly, or even clear
completely, in some children as they get older. The exact cause
of atopic eczema is unknown, but the imbalance of Th2 to Th1
cytokines plays a crucial role (David Boothe et al., 2017).























































4–5 years Chen et al., 2016
Autologous
hAT-MSCs
Case report 2 (1/1) 43 ± 21.2 2–3 intravenous
infusions of hAT MSCs
at a dose of
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Full Text View –
ClinicalTrials.gov)5
aExpression of measures: mean ± standard deviation (range).
1Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived Mesenchymal Stem Cells – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/NCT03765957?term=
mesenchymal+stem+cells&recrs=abdefgh&cond=Psoriasis&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=1 [Accessed January 13, 2021].
2Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment and PSORI-CM01 Granule in Psoriasis Patients – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/NCT04275024?
term=mesenchymal+stem+cells&recrs=abdefgh&cond=Psoriasis&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=1&rank=4 [Accessed January 21, 2021].
3Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/NCT03392311?term=
mesenchymal+stem+cells&recrs=abdefgh&cond=Psoriasis&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=1&rank=3 [Accessed January 21, 2021].
4Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/NCT03265613?term=
mesenchymal+stem+cells&recrs=abdefgh&cond=Psoriasis&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=2 [Accessed January 21, 2021].
5Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/NCT02918123?term=mesenchymal+
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Preclinical in vivo Studies
In the last 5 years, seven in vivo studies have reported the use of
hMSCs as advanced therapy (Table 8; Kim et al., 2015, Kim J.M.
et al., 2018; Shin et al., 2017; Sah et al., 2018; Lee et al., 2019; Park
et al., 2019, Park H.H. et al., 2020). The disease model preferred to
induce atopic dermatitis was the use of Dermatophagoides farina
extract alone (Kim et al., 2015; Shin et al., 2017) or combined
with other agents such as house dust mites (Park H.H. et al.,
2020) and 4% sodium dodecyl sulfate (SDS) (Lee et al., 2019).
Other substances used were ovalbumin (Sah et al., 2018), acetone
and 2, 4-dinitrochlorobenzene (DNCB): olive oil mixture (4:1
vol/vol) (Kim J.M. et al., 2018) and Aspergillus fumigatus extract
(Park et al., 2019).
Cell Therapy
Among studies reviewed, five reported the use of hMSCs as CT
(Table 8; Kim et al., 2015, Kim J.M. et al., 2018; Shin et al., 2017;
Lee et al., 2019; Park et al., 2019). Mean follow-up of these studies
was 14.4± 9.7 days and hMSCs analyzed were hUCB-MSCs (Kim
et al., 2015; Lee et al., 2019), hAT-MSCs (Shin et al., 2017; Kim
J.M. et al., 2018), and hWJ-MSCs (Park et al., 2019).
Kim et al. (2015) compared two administration routes: on
the one hand, injected 2 × 106 hUCB-MSCs intravenously
only or combined with a pretreatment of muramyl dipeptide.
On the other hand, also evaluated the same number of
cells injected subcutaneously combined with pretreatment of
muramyl dipeptide. In all cases, mice were treated on days 2,
9, 16, and 23 and results were compared with untreated and
healthy mice. Results indicated that subcutaneous administration
of hUCB-MSCs and muramyl dipeptide exhibited prominent
protective effects against atopic dermatitis, and suppressed the
infiltration and degranulation of mast cells (Kim et al., 2015). In
a similar way, Lee et al. (2019) explored the priming of hUCB-
MSCs with mast cells granules as potential strategy of treatment.
To that purpose they injected subcutaneously 106 hUCB-MSCs
primed or not with these granules reporting that preconditioning
with mast cells granules enhanced the therapeutic potential
of hUCB-MSCs against atopic dermatitis by improving the
immunosuppression and tissue regenerative capacity of the cells
and after 14 days, decreased the wound area by 20% more than
that achieved with naïve MSCs (Lee et al., 2019).
Regarding to the use of hAT-MSCs Shin et al. (2017) and Kim
J.M. et al. (2018) developed similar experiments where different
doses of hAT-MSCs were injected intravenously and this therapy
was compared with the injection of human dermal fibroblasts. In
the first study, the amount of cells injected were 2 × 105 and
2 × 106 demonstrating that administration of a high dose of
hAT-MSCs reduced the gross and histological signatures of atopic
dermatitis, as well as serum IgE level, mainly (Shin et al., 2017). In
the second case, two doses of 106 cells were injected intravenously
on days 0 and 11 revealing that hAT-MSCs attenuated clinical
symptoms associated with atopic dermatitis, decreased numbers
of degranulated mast cells (MCs), IgE level, amount of histamine
released, and prostaglandin E2 level (Kim J.M. et al., 2018).
Finally, Park et al. (2019) also evaluated the priming of hWJ-
MSCs for the treatment of atopic dermatitis. They compared the
subcutaneous administration of 2 × 106 cells alone, 2 × 106
cells primed with poly I:C and 2 × 106 cells primed with IFN-γ.
Results indicated that priming with poly I:C or IFN-γ affected the
immunomodulatory functions of hWJ-MSCs and enhanced their
therapeutic effects and alleviated the features of atopic dermatitis
including the clinical symptom score, transepidermal water loss
and epidermal thickness.
Combined advanced therapy: cell therapy and gene therapy
In addition to the previous studies, other two used a combination
of CT and GT (Sah et al., 2018; Park H.H. et al., 2020; Table 8),
where 2 × 106 hUCB-MSCs transduced with SOD3 (Sah et al.,
2018) or transfected with siRNA targeting TGF-β (Park H.H.
et al., 2020) were explored. In the first case (Sah et al., 2018),
transduced hUCB-MSCs treated mice showed stronger inhibition
of atopic dermatitis phenotype and epidermal hyperplasia and
dermal infiltration of mononuclear cells were decreased, but in
the case of cells transfected with siRNA targeting TGF-β (Park
H.H. et al., 2020), therapeutic effect was lower than in the case
of non-transfected cells which indicated that the role of TGF-β is
important for atopic dermatitis treatment.
Brief conclusion
On balance, the use of hMSCs for the treatment of atopic
dermatitis is well study at preclinical level. The main advanced
therapy strategy applied is cell therapy and the most analyzed
population of hMSCs used is hUCB-MSCs, however, the
application of gene therapy will require more safety analysis in
order to apply it into a clinical environment.
Clinical Studies
In the case of clinical research, five studies have reported the use
of hMSCs as advanced therapy for the treatment of moderate
to severe atopic dermatitis (Table 8). All applied cell therapy
strategy, however, only one has published results (Kim et al.,
2017), in contrast to the rest of clinical trials or observational
studies reviewed (NCT02888704, NCT03252340, NCT04179760,
and NCT04137562).
Allogeneic hMSCs were used in two of the cases (Kim
et al., 2017) (NCT04179760) and autologous cells in other
two (NCT02888704 and NCT03252340). In one of the
clinical trials, information about hMSCs’ donor was not
indicated (NCT04137562).
Regarding to the tissue source of different hMSC populations
analyzed; hUCB-MSCs, hBM-MSCs and hAT-MSCs were
used in one study each ((Kim et al., 2017), NCT04179760
and NCT04137562), but in two cases (interventional
and observational studies), origin was not indicated
(NCT02888704, NCT03252340).
Kim et al. (2017) evaluated safety and efficacy in 33
patients which received subcutaneous injections of allogeneic
hUCB-MSCs at two different doses (low dose; 2.5 × 107
cells or high dose; 5.0 × 107 cells). Results revealed that
adverse events such as skin infections, gastrointestinal disorders
or general disorders and administration site conditions were
observed in 12% of patients which received low dose of
hUCB-MSCs, in contrast to, 56% patients who received
the high dose. In terms of effectiveness, after 12 weeks,
Severity Scoring for Atopic Dermatitis (SCORAD) value



























TABLE 8 | Preclinical in vivo and clinical studies of hMSCs used as advanced therapy for atopic dermatitis in the last 5 years.




Cells Type of hMSC treatment evaluated Disease
models
Follow-up References
Cell therapy hUCB-MSCs 1-hUCB-MSCs group: 2 × 106 cells injected intravenously on days 2, 9, 16 and 23.
2-Muramyl dipeptide – hUCB-MSCs (intravenous) group: 2 × 106 injected intravenously
on days 2, 9, 16 and 23 previous administration of muramyl dipeptide. 3-Muramyl
dipeptide – hUCB-MSCs (subcutaneous) group: 2 × 106 injected subcutaneously on






30 days Kim et al., 2015
hAT-MSCs 1-hAT-MSCs (low) group: 2 × 105 cells injected intravenously 2-hAT-MSCs (high) group:







14 days Shin et al., 2017
hAT-MSCs 1-hAT-MSCs group: 106 cells injected intravenously on days 0 and 11 2-Fibroblasts









24 days Kim J.M. et al.,
2018
hUCB-MSCs 1-hUCB-MSCs group: subcutaneous administration of 106 cells 2-MC-hUCB-MSCs
primed group: subcutaneous administration of 106 cells primed with mast cells








14 days Lee et al., 2019
hWJ-MSCs 1-hWJ-MSCs group: subcutaneous administration of 2 × 106 cells 2-hWJ-MSCs-poly
I:C group: subcutaneous administration of 2 × 106 cells primed with poly I:C











hUCB-MSCs 1-hUCB-MSCs group: 2 × 106 cells injected subcutaneous on day 20, 28 and 42 and
one time on day 56 after the development of atopic dermatitis 2-hUCB-MSCs
transduced group: 2 × 106 superoxide dismutase 3 (SOD3) transduced cells injected







56 days Sah et al., 2018
hUCB-MSCs 1-hUCB-MSCs group: subcutaneous injection of 2 × 106 cells 2-hUCB-MSCs
transfected control group: subcutaneous injection of 2 × 106 cells transfected with
siRNA control 3-hUCB-MSCs transfected siTGF-β group: subcutaneous injection of
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aExpression of measures: mean ± standard deviation (range).
1Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/NCT04137562?term=
mesenchymal+stem+cells&recrs=abdefgh&cond=atopic+dermatitis&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=4 [Accessed January 21, 2021].
2Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/study/NCT02888704?
term=mesenchymal+stem+cells&recrs=abdefgh&cond=atopic+dermatitis&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=1 [Accessed January 21, 2021].
3Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/NCT04179760?term=mesenchymal+
stem+cells&recrs=abdefgh&cond=atopic+dermatitis&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=3 [Accessed January 21, 2021].
4Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/NCT03252340?term=
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was reduced in both groups (low dose: −28.04 ± 6.20%;
high dose: −49.97 ± 4.33%), demonstrating that single
administration of hUCB-MSCs improved atopic dermatitis
condition (Kim et al., 2017).
Considering the remaining studies, they compared the
intravenous injection of hMSCs; at different doses (1 × 108 cells
or 3 × 108 cells – NCT02888704), different time points (three
doses of 106 cells at weeks 0, 2 and 4 – NCT04179760) or to
evaluate the single administration of two injections of 0.5 × 108
cells (NCT04137562).
In contrast to preclinical level, the number of clinical studies
with published results is limited and there is not enough
information to stablish a standardized cell therapy based on the
use of hMSCs. However, promising results in animal models and
the incremental development of clinical trials could be beneficial
for the future treatment of atopic dermatitis.
Scleroderma
Scleroderma is a collective term covering a range of autoimmune
inflammatory conditions in which skin thickening (fibrosis)
or sclerosis is a hallmark feature (Orteu et al., 2020) due to
the excess production of collagen by the cells located in the
connective tissue. There are different subsets of the disease,
including localized scleroderma, limited cutaneous systemic
sclerosis, diffuse cutaneous systemic sclerosis, and systemic
sclerosis sine scleroderma (Fett, 2013).
Preclinical in vivo Studies
Since 2015, only one preclinical study has investigated the use
of hMSCs as advanced therapy for the treatment of scleroderma
(Maria et al., 2016; Table 9). In this case, the use of hBM-
MSCs and hAT-MSCs as CT was evaluated for the treatment of
systemic sclerosis (SSc) induced in mice. Results revealed that
the application of 2.5 × 106 hAT-MSCs injected intravenously
reported a significant reduction of skin thickness 21 days
after treatment and better results than hBM-MSCs application,
in terms of skin thickness reduction and extracellular matrix
deposition (Maria et al., 2016).
Clinical Studies
Ten clinical studies have reported the use of hMSCs as advanced
therapy for the treatment of systemic sclerosis in the last 5
years (Table 9; Granel et al., 2015; Guillaume-Jugnot et al., 2015;
Wehbe et al., 2016; Song et al., 2017; Virzì et al., 2017; Zhang
et al., 2017; Van Rhijn-Brouwer et al., 2018; Park Y. et al., 2020)
(NCT02975960 and NCT04356287). Among these studies, three
studies were case reports (Wehbe et al., 2016; Song et al., 2017;
Virzì et al., 2017), in contrast to the rest which were clinical trials.
Human MSCs used as CT were isolated from adipose tissue
(hAT-MSCs) (Granel et al., 2015; Guillaume-Jugnot et al., 2015;
Song et al., 2017; Virzì et al., 2017; Park Y. et al., 2020)
(NCT02975960), umbilical cord blood (hUCB-MSCs) (Wehbe
et al., 2016; Zhang et al., 2017) (NCT04356287), and bone marrow
(hBM-MSCs) (Van Rhijn-Brouwer et al., 2018). Interestingly,
in all cases where hAT-MSCs were used, autologous source
was preferred. However, when hUCB-MSCs or hBM-MSCs,
the origin was from allogeneic samples. Administration routes
applied were subcutaneous for hAT-MSCs, intravenous for
hUCB-MSCs and intramuscular for hBM-MSCs.
Among those studies which applied autologous hAT-MSCs
(n = 44), the number of cells injected varied from 3.76 ± 1.85
(1.19–7.07) × 106 (Granel et al., 2015; Guillaume-Jugnot et al.,
2015), 2.72 × 106 cells (Song et al., 2017) to 3.61 ± 4.34 × 106
(Park Y. et al., 2020). Interestingly, in one of the cases cells were
co-injected with PRP (Virzì et al., 2017). None adverse events
were observed, except in two cases where transient paresthesia,
pains or pallor in hands were observed (Granel et al., 2015;
Guillaume-Jugnot et al., 2015; Park Y. et al., 2020). Considering
effectiveness, those studies with published results demonstrated
the benefits of this methodology: Granel et al. and Guillaume-
Jugnot et al. compared the evolution of the disease from the
baseline to 12 months after treatment, reporting a significant
improvement of 46.8% for the Scleroderma Health Assessment
Questionnaire, of 51.3% for the Cochin Hand Function Scale
(CHFS) score and of 63.2% for the Raynaud’s Condition score
(Granel et al., 2015; Guillaume-Jugnot et al., 2015). Virzì
et al. (2017) observed that co-injection of PRP and hAT-MSCs
increased skin elasticity in perioral and malar areas (16.64%
for the lip and the 17.80% for the cheek) (Virzì et al., 2017);
and Park Y. et al. (2020) reported a slight improvement of
Raynaud’s Condition Scale value but without significance (from
5 to 6), although health assessment questionnaire reported better
values after 24 weeks (from 1.0 to 0.625) and better quality of
life was observed.
In the case of hUCB-MSCs, 34 patients has been recruited and
the number of cells for the treatment varied from 2× 106 cells/kg
(2 doses) (Wehbe et al., 2016), one injection of 8 × 106 cells/kg
(Zhang et al., 2017) and one or two injections of 106 cells/kg
(NCT04356287). Adverse events noted were upper respiratory
tract infections reported by five patients and diarrhea reported by
one patient during follow-up visits (Zhang et al., 2017). Results of
two patients treated by Wehbe et al. (2016) revealed that after one
year of treatment, European Scleroderma Study Group activity
index was reduced from 9.5 to 3.5 and 1.5, respectively (Wehbe
et al., 2016) which correlates with the study of Zhang et al. (2017)
where the mean Modified Rodnan skin score improved from
20.1± 3.1 to 13.8± 10.2 in 14 patients.
Finally, only one study evaluated the intramuscular injection
of 50× 106 allogeneic hBM-MSCs for the treatment of 10 patients
with systemic sclerosis (Van Rhijn-Brouwer et al., 2018) but there
is not results posted (NCT03211793).
On balance, despite of the fact that there were few preclinical
analysis, many clinical studies have evaluated the use of hMSCs as
CT for the treatment of scleroderma, reporting promising results,
however, increase the number of investigations and patients
is required to provide reliable information about the potential
benefits of these therapies.
Hypertrophic Scars
Hypertrophic scars are abnormal wound responses in
predisposed individuals. These fibrous growths result from
a connective tissue response to trauma, inflammation, surgery,
or burns and occasionally seem to occur spontaneously
(English and Shenefelt, 1999).



























TABLE 9 | Preclinical in vivo and clinical studies of hMSCs used as advanced therapy for scleroderma in the last 5 years.




Cells Type of hMSC treatment evaluated Disease models Follow-up References
Cell therapy hBM-MSCs and hAT-MSCs 1-hBM-MSCs group: intravenous infusion of 2.5 × 105 cells 2-hAT-MSCs group:
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Full Text View –
ClinicalTrials.gov)4
aExpression of measures: mean ± standard deviation (range).
1ADMSCs for the Treatment of Systemic Sclerosis – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/NCT02975960?term=mesenchymal+stem+cells&recrs=abdefgh&cond=
Scleroderma&strd_s=01%2F01%2F2015&strd_e=12%2F31%2F2020&draw=2&rank=1 [Accessed January 21, 2021].
2Allogeneic Mesenchymal Stem Cells Transplantation for Systemic Sclerosis (SSc) – Full Text View – ClinicalTrials.gov Available at: https://clinicaltrials.gov/ct2/show/NCT00962923 [Accessed February 14, 2021].
3Assessment of the Subcutaneous Reinjection of Human Autologous Adipose-derived Stromal Vascular Fraction (Celution§System) in the Hands of Patients Suffering From Systemic Sclerosis – Full Text View –
ClinicalTrials.gov Available at: https://clinicaltrials.gov/ct2/show/NCT01813279 [Accessed February 14, 2021].
4 Injection of Autologous Adipose-derived Stromal Vascular Fraction in the Finger of Systemic Sclerosis Patients – Full Text View – ClinicalTrials.gov Available at: https://clinicaltrials.gov/ct2/show/NCT03060551
[Accessed February 14, 2021].
5Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis – Full Text View – ClinicalTrials.gov Available at: https://www.clinicaltrials.gov/ct2/show/NCT04356287?term=
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Preclinical in vivo Studies
From 2015, many researches have explored the use of conditioned
media derived from hMSCs culture, however, only two studies
evaluated hMSCs as advanced therapy for the treatment of
hypertrophic scars at preclinical level (Table 10; Domergue et al.,
2016; Yates et al., 2017).
hAT-MSCs (Domergue et al., 2016) and hBM-MSCs (Yates
et al., 2017) have been the cells investigated as CT for
different in vivo models of hypertrophic scars (mean time
of follow-up: 25.5 ± 6.3 days). In the first case, to develop
hypertrophic scars, human skin grafts were engrafted into
mice wounds for 7 weeks and compared the subcutaneous
injection of 106 hAT-MSCs against the injection of stromal
vascular fraction (SVF) containing 106 hAT-MSCs, reporting
that one week after injection skin thickness tended to be lower
in both groups but reduction of skin thickness was more
significant in hAT-MSCs group, collagen fibers appeared less
dense an organized and fibrotic scar was reduced more efficiently
(Domergue et al., 2016).
Yates et al. (2017) used CXCR3 expression-abrogated mice
where wounds generated presented a visible scar, with a
thickened epidermis and a disorganized and hypercellular
dermis. Researchers compared different treatments combining
the injection of 106 hBM-MSCs/ml with other cell types
(fibroblasts), molecules (tenascin-C) or biomaterials (hyaluronic
acid or collagen I hydrogel). Results indicated that collagen–
tenascin-C matrix improved survival of MSCs and fibroblasts
and the use of hBM-MSCs increased migratory and proliferative
capacity of fibroblasts and also led to fewer inflammatory cells in
the wound, preventing hyper-keratinization, as well as excessive
matrix deposition.
On balance the use of hMSCs as cell therapy for the treatment
of hypertrophic scars seems to be interesting, however, the
lack of studies due to the minor impact into patient’s health
compared to the rest of skin diseases analyzed, makes necessary
to continue investigating.
Clinical Studies
As in the case of preclinical studies, the number of clinical
studies in the last 5 years is limited (Table 10). Only one study,
although design and results were published in two different
articles (Fan et al., 2018, 2020) and clinical trials (NCT02772289,
NCT04034615), has evaluated the transdermal injection of
allogeneic hUCB-MSCs for the treatment of scars derived from
caesarean sections at two different doses and compared the results
with a placebo. 90 patients (30 for each group), were treated with
an injection of 106 cells for continuous 3 days (low-dose), for
continuous 6 days (high-dose), or with placebo. Safety results
revealed that no obvious side effects or adverse effects were
reported and effectiveness was evaluated using the Vancouver
Scar Scale (VSS) score, demonstrating that after 6 months values
were lower (which means better) in the case of the high-dose
group against low-dose and placebo groups (4.71, 5.18, and 6.43,
respectively) (Fan et al., 2020).
Hypertrophic scars are not usually severe or life-threatening
injuries and for this reason, number of studies evaluating the
use of hMSC-based advanced therapies is limited. However, their
esthetic implications could affect on mental health status of
patients which has a direct impact on their quality of life, so the
search of more successful treatments seems to be required.
Other Dermatological Pathologies
Apart from the previous dermatological diseases reviewed there
are others such as photoaging and acne which are less aggressive
or conventional and effective treatments exist. In other cases,
diseases such as vitiligo and hidradenitis suppurative (Cuenca-
Barrales et al., 2020) affect to a minor population or there is
not an effective treatment. In these cases, the number of studies
reporting the use of hMSCs in the last 5 years is limited.
Among them, only one in vitro preclinical study reported the
use of hMSCs (source was not indicated) for the treatment of
vitiligo, a chronic disorder characterized by depigmented patches
in the skin that are caused by deficiency or dysfunction in
melanocytes. In this study, cocultured hMSCs with 10 different
melanocyte pools reported an improved cell proliferation and
suppressed apoptosis in melanocytes (Zhu et al., 2020).
In the case of clinical studies, only one administered
autologous hAT-MSCs as CT for the treatment of photoaged
skin. 20 patients (56 ± 2.53 years old) extensive exposed to
sun and presenting Fitzpatrick class IV (n = 9) and class V
(n = 11) skin, were treated. One year after subdermal injection
of hAT-MSCs in preauricular region, non-adverse events were
observed. Results revealed an extensive new production and
regeneration of elaunin, oxytalan, and elastin fiber network
located in the upper papillary dermis, concomitant with
degradation of elastotic abnormal elastin deposits in the deeper
dermal layers, which is the major characteristic of solar elastosis
(Charles-De-Sá et al., 2020).
Other important cutaneous diseases not included in this
review are alopecia and toxic skin injuries. In the first case,
our group has recently published a comprehensive review where
many advanced therapy has been analyzed including those using
hMSCs (Martinez-Lopez et al., 2020). In the case of toxic skin
conditions, many chemical agents could impair skin barrier and
another review could be wrote about their possible treatment,
however, in recent years, skin injuries generated by sulfur
mustard (SM) agent have been analyzed (Rose et al., 2018) and
the potential use of hMSCs-based advanced therapy could be
interested because SM damage DNA of mesenchymal stem cells
provoking less proliferative and migratory capacities (Schmidt
et al., 2018; Schreier et al., 2018).
DISCUSSION
Conventional treatments for wounds, chronic ulcers or severe
burns have been based on skin autografts, or allografts, however,
the lack of donor’s tissue, the risk associated to the surgery
and the possibility of immune rejection in the case of allografts
(Brockmann et al., 2018) has made necessary to search for new
alternatives. In other cases, such as psoriasis or atopic dermatitis,
immunological profile plays a crucial role in the disease’s
development, so the main commercialized drugs try to regulate
this aspect, although there is not a 100% effective treatment.



























TABLE 10 | Preclinical in vivo and clinical studies of hMSCs used as advanced therapy for hypertrophic scars in the last 5 years.




Cells Type of hMSC treatment evaluated Animals Disease models Follow-up References
Cell therapy hAT-MSCs 1-hAT-MSCs group: subcutaneous injection of
106 cells 2-Stromal vascular fraction (SVF)
group subcutaneous injection of SVF containing
106 hAT-MSCs 3-Control group: subcutaneous





Human skin samples were grafted into
mice for 7 weeks to develop
hypertrophic scars
21 days Domergue et al., 2016
hBM-MSCs 1-hBM-MSCs group: addition to the wound of
106 cells/ml 2-hBM-MSCs + collagen
I-tenascin-C (TNC) group: addition to the
wound of 106 cells/ml + collagen I-tenascin-C
(TNC) 3-hBM-MSCs + fibroblasts + hyaluronic
acid (HA) group: addition to the wound of 106
cells/ml + fibroblasts + HA
4-hBM-MSCs + fibroblasts + collagen
I-TNC + hyaluronic acid (HA) group: addition to
the wound of 106







Wounds these mice presented a visible
scar, a thickened epidermis, and a
disorganized and hypercellular dermis
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Fan et al., 2018; Fan et al.,
2020 NCT02772289 (Perinatal
Tissue Mesenchyme Stem
Cells in the Treatment for
Caesarean Section Scars – Full
Text View – ClinicalTrials.gov)1
NCT04034615 (Injection of
Autologous Adipose-derived
Stromal Vascular Fraction in the
Finger of Systemic Sclerosis
Patients – Full Text View –
ClinicalTrials.gov)2
aExpression of measures: mean ± standard deviation (range).
1Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars – Full Text View – ClinicalTrials.gov Available at: https://clinicaltrials.gov/ct2/show/NCT02772289 [Accessed February 14, 2021].
2 Injection of Autologous Adipose-derived Stromal Vascular Fraction in the Finger of Systemic Sclerosis Patients – Full Text View – ClinicalTrials.gov Available at: https://clinicaltrials.gov/ct2/show/NCT03060551
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Searching new alternatives for the treatment of skin disorders
is an interesting field; the most promising results have been
achieved for wounds, burns and ulcers where many tissue-
engineered skin substitutes (TESSs) has been developed. Until
now, most of these therapies are based on acellular biomaterials
or different scaffolds in combination with autologous skin
cells, fibroblasts and keratinocytes mainly (Germain et al.,
2018; Meuli et al., 2019), to avoid immunological rejection.
Although preclinical and clinical research has reported positive
results, only few commercial TESSs are available on market
due to the cost and the associated toxicity of biomaterials
(Brockmann et al., 2018).
For these reasons, the use of hMSCs for the treatment
of skin diseases and injuries is a promising strategy due to
their regenerative and immunomodulatory capacities previously
reviewed (Diehl et al., 2017). Since 2015, 46 preclinical
in vivo studies (mouse and rat models) and 54 clinical
studies (1316 patients) have evaluated the use of hMSCs as
advanced therapy (Supplementary Table 1); however, wounds,
ulcers, burns injuries, and psoriasis are the most analyzed
pathological conditions.
Focusing only in clinical essays, cell therapy is the most
investigated strategy (43 vs. 10 TE studies – Figure 1), probably
due to the difficulties associated to the fabrication of TESS (TE) or
the development of engineered cells (GT), which requires specific
formation and manufacturing conditions. However, in the case
of the wounds and ulcers, the number of studies is equated (8
CT vs. 8 TE) because of the small size of injuries, in comparison
to severe burns, and the low immunogenic profile of hMSCs
(Diehl et al., 2017).
Another important topic to consider is the autologous or
allogeneic nature of cells reviewed: 40 studies have evaluated
allogeneic hMSCs but only 12 have reported the use of autologous
cells. In contrast to investigations where autologous adult
cells are analyzed, where manufacturing time is longer, the
immunomodulatory capacity of allogeneic hMSCs seems to be an
advantage, because the rapid availability associated could increase
the success rate. At this point, cryopreservation of allogeneic
cells is an important issue to consider, because in some cases the
potential benefits of these therapies have been affected (Weise
et al., 2014). However, recent studies have determined that apart
from cryopreservation, thawing is also more important to avoid
a failure of these therapies, demonstrating that culturing these
cells for 24 h after thawing, allowed to recover functional potency
of hMSCs and, even, their immunosuppressive capacity was
increased (Antebi et al., 2019).
Although CT based on the use of hMSCs is the predominant
strategy for all pathologies reviewed, there is not a standardized
number of cells, doses, or routes of administration, even if
each disease is analyzed separately. This is a limitation, due
to the impossibility of stablishing a common therapy and
comparing results among studies; for example, in the case
of burn injuries, treatment differs from injection around the
wounds to topical application, meanwhile, in psoriasis, atopic
dermatitis or scleroderma, although most of the studies evaluated
intravenous administration; subcutaneous or intramuscular
injections were also reported.
Considering intravenous administration as one of the main
strategies, migration capacity of hMSCs must be studied. This
property has been evaluated and increased for the treatment
of strokes in a mouse model (Jablonska et al., 2018) or
cerebral embolism in rats (Cui et al., 2017), demonstrating its
benefits. In the case of cutaneous diseases, an in vitro study
demonstrated that regenerative and migratory potential could be
increased after culturing hMSCs with CCL5/Rantes (Kroeze et al.,
2009). However, therapeutic potential of hMSCs in psoriasis or
atopic dermatitis is focused in their capacity to counteract the
recruitment capacity of the own pathological hMSCs which are
responsible of provoking an excessive angiogenesis (Han et al.,
2021) or inflammatory cell infiltration (Niu et al., 2019), and
therefore, aggravate extent of the disease.
Analysis of hMSCs’ tissue sources revealed that mesenchymal
stem cells isolated from adipose tissue (hAT-MSCs), bone
marrow (hBM-MSCs) or umbilical cord blood (hUCB-MSCs) are
the preferred sources, although in all cases results were positive.
hAT-MSCs were studied in 30 cases (9 preclinical and 21 clinical),
hBM-MSCs in 14 (4 vs. 10) and hUCB-MSCs in 32 (19 vs. 13)
(Supplementary Table 1). This means that despite of the fact that
for research, hUCB-MSCs are the most investigated because they
are easy to obtain from tissue and cell banks; for clinical purposes,
hAT-MSCs seems to be the best option.
An overview of each pathology reviewed and their clinical
studies, revealed that for wounds and ulcers, allogeneic
hAT-MSCs was the cell population most investigated
and engraftment of TESSs constituted of hMSCs was the
preferred strategy. In the case of burn injuries and psoriasis,
allogeneic hAT-MSCs was also the most analyzed cell type but
administered by topical application or intravenous injection,
respectively. For scleroderma, autologous hAT-MSCs injected
subcutaneously was the most investigate cell therapy, and
for RDEB, allogeneic hBM-MSCs applied intravenously.
Finally, for atopic dermatitis and hypertrophic scars there
was not a preferred hMSC population, but the most analyzed
administration routes were intravenous and transdermal
injections, respectively.
Potential benefits of using hAT-MSCs are due to their
ability of secreting a lot of factors which are involved in cell
proliferation, migration, and improvement of cellular and
microenvironment protection (Mazini et al., 2020), apart
from their immunomodulatory properties to inactivate T cells
(Jacobs et al., 2013) and modulate the inflammatory phenotype
of local immune cells to a healing anti-inflammatory one
(Mazini et al., 2020) which have implications in psoriasis,
atopic dermatitis and scleroderma. The release of growth
factors by hAT-MSCs increase the expression of genes
related with skin regeneration, such as CD34, collagen type
1 or elastin and moreover, stimulate the proliferation of
human fibroblasts (Choi et al., 2018) and the activation of
AKT and ERK signaling pathways in human endothelial
cells, keratinocytes, and fibroblasts which demonstrate
their potential implications in wound healing (Ren et al.,
2019). Most of these characteristics are also observed in
other hMSCs, such as those derived from bone marrow
(Pachón-Peña et al., 2011).
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For all of this, apart from the direct use of hMSCs, many
recent preclinical studies have evaluated the use of exosomes
and conditioned mediums derived from them. These released
molecules, alone or combine with other substances or scaffolds,
have reported successful result in terms of wound closure and re-
epithalization (Shabbir et al., 2015; Tao et al., 2017; Aryan et al.,
2019; Dalirfardouei et al., 2019; Wang et al., 2019; Zhou et al.,
2019; Jiang et al., 2020).
On balance, we consider that the use of hMSCs-based
advanced therapies for the treatment of dermatological
pathologies could increase patient’s health and quality of life
in a significant way. On the one hand, the use of these cells
helps to increase the regenerative capacity of the own patient’s
hMSCs due to their role in wound healing and, on the other
hand, the immunomodulatory capacities associated to them, are
important to regulate the immunological response in diseases
such as psoriasis or atopic dermatitis. However, despite of the
fact that many promising advanced therapies based on the use
of hMSCs have been developed and evaluated in the last years,
this review remarks the necessity of increasing the investigation
at preclinical level. The main animal models analyzed were
mice and rats, however, to validate these therapies, pigs or apes
would be better to resemble human wounds or diseases. In
addition, more clinical research is required to evaluate safety
and effectiveness, because in most of the cases, results have been
not published yet or none control groups have been included.
Particularly, for RDEB, the use of cells genetically modified in
a clinical environment would be the most interesting therapy,
however, the lack of information about the long-term effect of this
strategy, makes difficult to develop clinical trials. In conclusion,
filling all these aspects would help to determine the best strategy,
source of hMSCs and doses of treatment for each cutaneous
disease or injury.
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